Research programme: fatty acid amide hydrolase inhibitors - Vernalis
Latest Information Update: 18 Mar 2011
At a glance
- Originator Vernalis
- Mechanism of Action Fatty acid amide hydrolase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Pain
Most Recent Events
- 17 Mar 2011 This programme is still in active development
- 27 Aug 2010 Preclinical development is ongoing in the United Kingdom